MCRB Seres Therapeutics
- 1.000
- +0.026+2.67%
- 1.000
- 0.0000.00%
Seres Therapeutics News
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 26% But Investors Aren't Buying For Growth
Seres Therapeutics, Inc. (NASDAQ:MCRB) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up recently lost ground.
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $15
CCORF analyst John Newman maintains $Seres Therapeutics(MCRB.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 38.5% and a tot
Analysts Conflicted on These Healthcare Names: Seres Therapeutics (MCRB) and Immunocore Holdings (IMCR)
Seres Therapeutics(MCRB.US) Officer Sells US$882.66 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer von Moltke Lisa sold 939 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $882.66.Source: Announcement What is statement o
Seres Therapeutics(MCRB.US) Officer Sells US$2,288.9 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Shaff Eric D. sold 2,435 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $2,288.9.Source: Announcement What is statement
Seres Therapeutics(MCRB.US) Officer Sells US$660.82 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Young Teresa L. sold 703 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $660.82.Source: Announcement What is statement o
Seres Therapeutics(MCRB.US) Officer Sells US$837.54 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Henn Matthew R. sold 891 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $837.54.Source: Announcement What is statement o
Seres Therapeutics(MCRB.US) Officer Sells US$792.42 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer DesRosier Thomas sold 843 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $792.42.Source: Announcement What is statement
Seres Therapeutics(MCRB.US) Officer Sells US$1,024.6 in Common Stock
$Seres Therapeutics(MCRB.US)$ Officer Ege David S. sold 1,090 shares of common stock on May 15, 2024 at an average price of $0.94 for a total value of $1,024.6.Source: Announcement What is statement o
Buy Rating on Seres Therapeutics Backed by Strong SER-155 Study Progress and Potential in Transplant Health
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Seres Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 412.89% Oppenheimer $5 → $4 Maintains Outperform 05/08/2024 669.33% Chardan Capital $8 → $6 Mai
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmbecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out to
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Express News | Seres Therapeutics : Oppenheimer Cuts Target Price to $4 From $5
Buy Rating Affirmed for Seres Therapeutics Amidst Strong Sales Trajectory and Promising Pipeline
Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating
Seres Therapeutics (MCRB) has an average rating of outperform and price targets ranging from $1.10 to $15, according to analysts polled by Capital IQ. Price: 0.7600, Change: +0.01, Percent Change: +1.
Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
Analysis
Price Target
No Data
